Emetine enhances the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of pancreatic cancer cells by downregulation of myeloid cell leukemia sequence-1 protein

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 456-462

  Han, Yujeong ^a   Park, Sojung ^a   Kinyua, Ann W ^c   Andera, Ladislav ^d   Kim, K I Woo ^c   Kim, Inki ^a,b  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Yonsei University Wonju College of Medicine   (South Korea)

^d INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Apoptosis; Emetine; Mcl 1; Pancreatic cancer; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; BREFELDIN A; CPG 74514A; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EMETINE; MYELOID LEUKEMIA FACTOR 1; SMALL INTERFERING RNA; TOPOTECAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL HYPOXIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG POTENTIATION; DRUG SPECIFICITY; GENE EXPRESSION REGULATION; GENE SILENCING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; EMETINE; HUMANS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PANCREATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84891911666     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2838     Document Type: Article

References (50)

1. Schneider G, Siveke JT, Eckel F and Schmid RM: Pancreatic cancer: basic and clinical aspects. Gastroenterology 128: 1606?1625, 2005.
2. Wong HH and Lemoine NR: Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6: 412-422, 2009.
3. Hamacher R, Schmid RM, Saur D and Schneider G: Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 7: 64, 2008.
4. Favaloro B, Allocati N, Graziano V, Di Ilio C and De Laurenzi V: Role of apoptosis in disease. Aging (Albany NY) 4: 330-349, 2012.
5. Lavrik I, Golks A and Krammer PH: Death receptor signaling. J Cell Sci 118: 265-267, 2005.
6. Pan G, O'Rourke K, Chinnaiyan AM, et al: The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113, 1997.
7. Ashkenazi A and Dixit VM: Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11: 255-260, 1999.
8. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996.
9. Bellail AC, Qi L, Mulligan P, Chhabra V and Hao C: TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4: 34-41, 2009.
10. Van Geelen CM, de Vries EG and de Jong S: Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 7: 345-358, 2004.
11. Bhojani MS, Rossu BD and Rehemtulla A: TRAIL and anti-tumor responses. Cancer Biol Ther 2: S71-S78, 2003.
12. Koschny R, Walczak H and Ganten TM: The promise of TRAIL - potential and risks of a novel anticancer therapy. J Mol Med (Berl) 85: 923-935, 2007.
13. Wang P, Zhang J, Bellail A, et al: Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 19: 2237-2246, 2007.
14. Hylander BL, Pitoniak R, Penetrante RB, et al: The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3: 22, 2005.
15. Zhang Y and Zhang B: TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 6: 1861-1871, 2008.
16. Fisher MJ, Virmani AK, Wu L, et al: Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 7: 1688-1697, 2001.
17. Kim K, Fisher MJ, Xu SQ and el-Deiry WS: Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6: 335-346, 2000.
18. Shin MS, Kim HS, Lee SH, et al: Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 61: 4942-4946, 2001.
19. Nakshatri H, Rice SE and Bhat-Nakshatri P: Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23: 7330-7344, 2004.
20. Ryu BK, Lee MG, Chi SG, Kim YW and Park JH: Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 194: 15-19, 2001.
21. Okano H, Shiraki K, Inoue H, et al: Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83: 1033-1043, 2003.
22. Fulda S, Meyer E and Debatin KM: Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21: 2283-2294, 2002.
23. Eggert A, Grotzer MA, Zuzak TJ, et al: Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61: 1314-1319, 2001.
24. Daniel PT, Wieder T, Sturm I and Schulze-Osthoff K: The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 15: 1022-1032, 2001.
25. Gasparian ME, Chernyak BV, Dolgikh DA, et al: Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. Apoptosis 14: 778-787, 2009.
26. Gasparian ME, Ostapchenko VG, Yagolovich AV, et al: Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase. Biotechnol Lett 29: 1567-1573, 2007.
27. Sah NK, Munshi A, Kurland JF, McDonnell TJ, Su B and Meyn RE: Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem 278: 20593-20602, 2003.
28. Hellwig CT, Kohler BF, Lehtivarjo AK, et al: Real time analysis of tumor necrosis factor-related apoptosis-inducing ligand/cyclo-heximide-induced caspase activities during apoptosis initiation. J Biol Chem 283: 21676-21685, 2008.
29. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
30. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
31. Mahalingam D, Szegezdi E, Keane M, de Jong S and Samali A: TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 35: 280-288, 2009.
32. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR and Yagita H: Nature's TRAIL - on a path to cancer immunotherapy. Immunity 18: 1-6, 2003.
33. Lambert AC: The treatment of amoebic dysentery with emetine and bismuth iodide. Br Med J 1: 116-118, 1918.
34. Mackey-Lawrence NM and Petri WA Jr: Amoebic dysentery. Clin Evid (Online) 2011: pii 0918, 2011.
35. Grollman AP: Structural basis for inhibition of protein synthesis by emetine and cycloheximide based on an analogy between ipecac alkaloids and glutarimide antibiotics. Proc Natl Acad Sci USA 56: 1867-1874, 1966.
36. Bicknell GR, Snowden RT and Cohen GM: Formation of high molecular mass DNA fragments is a marker of apoptosis in the human leukaemic cell line, U937. J Cell Sci 107: 2483-2489, 1994.
37. Watanabe N, Iwamoto T, Dickinson DA, Iles KE and Forman HJ: Activation of the mitochondrial caspase cascade in the absence of protein synthesis does not require c-Jun N-terminal kinase. Arch Biochem Biophys 405: 231-240, 2002.
38. Meijerman I, Blom WM, de Bont HJ, Mulder GJ and Nagelkerke JF: Induction of apoptosis and changes in nuclear G-actin are mediated by different pathways: the effect of inhibitors of protein and RNA synthesis in isolated rat hepatocytes. Toxicol Appl Pharmacol 156: 46-55, 1999.
39. Moller M, Weiss J and Wink M: Reduction of cytotoxicity of the alkaloid emetine through P-glycoprotein (MDR1/ABCB1) in human Caco-2 cells and leukemia cell lines. Planta Med 72: 1121-1126, 2006.
40. Rosenkranz V and Wink M: Alkaloids induce programmed cell death in bloodstream forms of trypanosomes (Trypanosoma b. brucei). Molecules 13: 2462-2473, 2008.
41. Boon-Unge K, Yu Q, Zou T, Zhou A, Govitrapong P and Zhou J: Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism. Chem Biol 14: 1386-1392, 2007.
42. Moller M, Herzer K, Wenger T, Herr I and Wink M: The alkaloid emetine as a promising agent for the induction and enhancement of drug-induced apoptosis in leukemia cells. Oncol Rep 18: 737-744, 2007.
43. Pan D, Boon-Unge K, Govitrapong P and Zhou J: Emetine regulates the alternative splicing of caspase 9 in tumor cells. Oncol Lett 2: 1309-1312, 2011.
44. Zhong Q, Gao W, Du F and Wang X: Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121: 1085-1095, 2005.
45. Koong AC, Mehta VK, Le QT, et al: Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48: 919-922, 2000.
46. Oh B, Park S, Pak JH and Kim I: Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand. Biochem Biophys Res Commun 422: 42-47, 2012.
47. Kelly MM, Hoel BD and Voelkel-Johnson C: Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 1: 520-527, 2002.
48. Kim DR, Park MY, Lee CS, et al: Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. Cancer Gene Ther 18: 467-477, 2011.
49. Ciusani E, Croci D, Gelati M, et al: In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. J Neurooncol 71: 19-25, 2005.
50. Yoo J, Park SS and Lee YJ: Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells. J Cell Biochem 104: 1636-1646, 2008.